Research Progress of ARID1A and PIK3CA Mutations in Malignant Transformation of Ovarian Endometriosis

doi:10.12280/gjfckx.20240878

Abstract

Abstract:

Endometriosis (EMs) is a common gynecological disease with a prevalence of 6% to 10% in women of reproductive age. Although endometriosis is morphologically benign, it is susceptible to implantation, invasion and distant metastasis. Ovarian endometriosis is one of the most common forms of endometriosis, which is prone to recurrence after treatment and poses a serious threat to female reproductive health. In recent years, a large number of studies have found that ovarian endometriosis has the potential for malignant transformation into ovarian cancer. In the malignant transformation process of ovarian endometriosis, the most common mutations are in the ARID1A and PIK3CA genes, which occur in the early stage of malignancy. The current status of ARID1A and PIK3CA mutations in malignant transformation of ovarian endometriosis is reviewed.

Key words: Endometriosis, Ovarian neoplasms, Genes, Mutation, ARID1A, PIK3CA

ZHANG Yun-feng, ZHANG Wan-yue, LU Yue, WANG Yang-yang, JING Jia-yu, MU Jing-yi, WANG Yue. Research Progress of ARID1A and PIK3CA Mutations in Malignant Transformation of Ovarian Endometriosis[J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 19-22.

References 28

[1]	Horne AW, Missmer SA. Pathophysiology, diagnosis, and management of endometriosis[J]. BMJ, 2022,379:e070750. doi: 10.1136/bmj-2022-070750.
[2]	Guidozzi F. Endometriosis-associated cancer[J]. Climacteric, 2021, 24(6):587-592. doi: 10.1080/13697137.2021.1948994.
[3]	郎景和. 子宫内膜异位症和肿瘤兼论子宫内膜异位症恶变[J]. 中华妇产科杂志, 2019, 54(9):577-581. doi: 10.3760/cma.j.issn.0529-567x.2019.09.001.
[4]	Odnokoz O, Wavelet-Vermuse C, Hophan SL, et al. ARID1 proteins: from transcriptional and post-translational regulation to carcinogenesis and potential therapeutics[J]. Epigenomics, 2021, 13(10):809-823. doi: 10.2217/epi-2020-0414. pmid: 33890484
[5]	Zhang X, Zhang Y, Zhao J, et al. ARID1A mutations in cancer development: mechanism and therapy[J]. Carcinogenesis, 2023, 44(3):197-208. doi: 10.1093/carcin/bgad011. pmid: 36882165
[6]	Lu S, Duan R, Cong L, et al. The effects of ARID1A mutation in gastric cancer and its significance for treatment[J]. Cancer Cell Int, 2023, 23(1):296. doi: 10.1186/s12935-023-03154-8. pmid: 38008753
[7]	Peerapen P, Sueksakit K, Boonmark W, et al. ARID1A knockdown enhances carcinogenesis features and aggressiveness of Caco-2 colon cancer cells: An in vitro cellular mechanism study[J]. J Cancer, 2022, 13(2):373-384. doi: 10.7150/jca.65511.
[8]	Mullen J, Kato S, Sicklick JK, et al. Targeting ARID1A mutations in cancer[J]. Cancer Treat Rev, 2021,100:102287. doi: 10.1016/j.ctrv.2021.102287.
[9]	Steinbuch SC, Lüß AM, Eltrop S, et al. Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance[J]. Int J Mol Sci, 2024, 25(8):4306. doi: 10.3390/ijms25084306.
[10]	Driva TS, Schatz C, Haybaeck J. Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis[J]. Biomolecules, 2023, 13(8):1253. doi: 10.3390/biom13081253.
[11]	Liu G, Xu P, Fu Z, et al. Prognostic and Clinicopathological Significance of ARID1A in Endometrium-Related Gynecological Cancers: A Meta-Analysis[J]. J Cell Biochem, 2017, 118(12):4517-4525. doi: 10.1002/jcb.26109. pmid: 28466574
[12]	Heckl M, Schmoeckel E, Hertlein L, et al. The ARID1A, p53 and β-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium[J]. PLoS One, 2018, 13(2):e0192881. doi: 10.1371/journal.pone.0192881.
[13]	Peng Y, Wang Y, Zhou C, et al. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?[J]. Front Oncol, 2022,12:819128. doi: 10.3389/fonc.2022.819128.
[14]	Mishra R, Patel H, Alanazi S, et al. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects[J]. Int J Mol Sci, 2021, 22(7):3464. doi: 10.3390/ijms22073464.
[15]	Madsen RR, Semple RK. PIK3CA-related overgrowth: silver bullets from the cancer arsenal?[J]. Trends Mol Med, 2022, 28(4):255-257. doi: 10.1016/j.molmed.2022.02.009. pmid: 35272946
[16]	Montoro-Jiménez I, Granda-Díaz R, Menéndez ST, et al. Combined PIK3CA and SOX2 Gene Amplification Predicts Laryngeal Cancer Risk beyond Histopathological Grading[J]. Int J Mol Sci, 2024, 25(5):2695. doi: 10.3390/ijms25052695.
[17]	Tan ES, Fan W, Knepper TC, et al. Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer[J]. Target Oncol, 2022, 17(4):483-492. doi: 10.1007/s11523-022-00898-7. pmid: 35767139
[18]	Shi Q, Xuhong J, Tian H, et al. Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis[J]. Biochim Biophys Acta Rev Cancer, 2023, 1878(1): 188847. doi: 10.1016/j.bbcan.2022.188847.
[19]	Choi JH, Yu J, Jung M, et al. Prognostic significance of TP53 and PIK3CA mutations analyzed by next-generation sequencing in breast cancer[J]. Medicine(Baltimore), 2023, 102(38):e35267. doi: 10.1097/MD.0000000000035267.
[20]	Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma[J]. J Pathol, 2011, 225(2):189-194. doi: 10.1002/path.2940.
[21]	Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma[J]. Virchows Arch, 2012, 460(1):77-87. doi: 10.1007/s00428-011-1169-8.
[22]	Passarelli A, Carbone V, Pignata S, et al. Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity[J]. Gynecol Oncol, 2024, 183:61-67. doi: 10.1016/j.ygyno.2024.02.029. pmid: 38518529
[23]	Anabel Sinberger L, Zahavi T, Sonnenblick A, et al. Coexistent ARID1A-PIK3CA mutations are associated with immune-related pathways in luminal breast cancer[J]. Sci Rep, 2023, 13(1):20911. doi: 10.1038/s41598-023-48002-x.
[24]	Tharin Z, Richard C, Derangère V, et al. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy[J]. Sci Rep, 2023, 13(1):4467. doi: 10.1038/s41598-023-31593-w. pmid: 36934165
[25]	Sun Y, Liu G. Endometriosis-associated Ovarian Clear Cell Carcinoma: A Special Entity?[J]. J Cancer, 2021, 12(22):6773-6786. doi: 10.7150/jca.61107. pmid: 34659566
[26]	Bolton KL, Chen D, Corona de la Fuente R, et al. Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes[J]. Clin Cancer Res, 2022, 28(22):4947-4956. doi: 10.1158/1078-0432.CCR-21-3817. pmid: 35816189
[27]	Gao N, Flynn DC, Zhang Z, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells[J]. Am J Physiol Cell Physiol, 2004, 287(2):C281-C291. doi: 10.1152/ajpcell.00422.2003.
[28]	Chandler RL, Damrauer JS, Raab JR, et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling[J]. Nat Commun, 2015,6:6118. doi: 10.1038/ncomms7118.